Past exam of the biochemistry course of the University of Cambridge / 2024 / Paper 5

The viral DNA is copied by semiconservative replication and its labelling kinetics broadly follow those of host DNA during viral latency. At the earliest time the newly labelled material is mainly hybrid: an old light strand has acquired a heavy complementary strand. Fully heavy duplexes accumulate later, after heavy strands themselves serve as templates. Conservative copying would instead produce a separate fully heavy population from the first copying round, while dispersive copying would produce progressively shifting intermediate densities rather than these three discrete classes.

For an ideal synchronous population starting entirely light, one complete round gives only hybrid duplexes; after $n\ge 1$ rounds the hybrid fraction is $2^{1-n}$ and the fully heavy fraction is $1-2^{1-n}$. The actual culture is asynchronous, so these integer-generation proportions cannot simply be imposed at $t/23$ hours. The similar viral and cellular bars support replication coordinated with cell proliferation rather than rapid autonomous amplification. They do not establish that every episome initiates exactly once in every individual biological cell, or prove an initiation time within S phase. Persistent light material also warns against treating the population as a perfectly uniform set of cycling biological cells. The strand-accounting principle is the one tested in ^[ref].

Base composition changes both the initial buoyant density and the size of the BUdR-induced density increment. The fraction-number axis runs toward lower density. The unlabelled viral peak lies at a lower fraction number than the corresponding host peak, consistent with viral DNA having a higher GC content. BUdR replaces thymidine in newly synthesized strands, so relatively AT-rich DNA incorporates more brominated nucleoside per unit length and undergoes a larger density increase.

Consequently the more AT-rich host DNA can overtake the viral DNA in the fully substituted class: the host fully heavy peak is slightly farther toward the dense end, although host unlabelled DNA was less dense. The hybrid peaks are intermediate. A useful qualitative model is ${\rho }_{LL}={\rho }_0(g)$, ${\rho }_{LH}={\rho }_0(g)+\Delta \rho (g)/2$ and ${\rho }_{HH}={\rho }_0(g)+\Delta \rho (g)$, where $g$ is GC fraction, ${\rho }_0$ increases with $g$, and $\Delta \rho$ decreases as the thymidine fraction decreases. Unequal substitution efficiencies could contribute, but different replication mechanisms are unnecessary. These are equilibrium density positions, not molecular-length measurements.

The DNA-binding domain supports site occupancy, while the region for homotypic protein interaction permits much larger assemblies. With the truncated protein, the faster complex 4 appears at low protein:DNA ratios and gives way to the slower complex 3 as protein increases. A natural assignment is occupancy of one and then both recognition repeats by functional binding units. A binding unit could itself be a protein dimer; a native gel does not determine the number of polypeptide chains from mobility alone. Loss of free probe with increasing protein supports binding, and failure to shift the zero-repeat probe supports sequence preference under these conditions.

Full-length protein instead produces the very slow complex 1 already at relatively low ratios, followed by more of complex 2 at high ratios. homotypic protein interactions can make cooperative higher-order assemblies and can bridge different probe molecules. At protein excess, separate saturation of available sites can reduce productive bridging, explaining why the largest species need not increase monotonically. Complex 2 is compatible with a smaller saturated full-length assembly; assigning its exact stoichiometry requires an independent measurement. protein size also contributes to the difference between full-length and truncated complexes, but size alone does not explain the concentration-dependent redistribution into the exceptionally slow species. The experiment supports assembly dependent on protein oligomerization rather than a unique structure for every numbered band.

At low concentration, the array with more and higher-affinity binding sites is preferentially occupied, giving one visible protein cluster on an otherwise extended DNA molecule. At higher concentration the weaker origin array also becomes occupied. homotypic protein interactions between proteins at the two arrays can bridge them, trapping the intervening DNA through DNA looping. This explains why the electron-dense protein cluster lies at the loop junction rather than uniformly coating the entire molecule.

The high-affinity array can stabilize weak-site occupancy through tethering: once one partner is anchored, the second site experiences a high effective local concentration and several contacts can contribute avidity. This reconciles stable looped assemblies with the vulnerability of the isolated weak site to nonspecific competitor DNA. The images support intramolecular DNA bridging, but selected micrographs do not measure its frequency or exclude some intermolecular associations. A high local density of protein need not imply biomolecular phase separation. The printed scale-bar unit appears implausible for a kilobase-scale DNA substrate; the mechanistic inference uses topology and site positions rather than that unit.

Latent viral DNA has regularly spaced nucleosome protection, whereas much of the nuclear viral DNA during productive infection lacks that regular protection. In the latent sample, increasing digestion resolves a ladder of protected fragments, as expected when micrococcal nuclease cuts exposed linker DNA between nucleosomes. In the productive sample, viral signal is lost rapidly into heterogeneous small material rather than accumulating as a comparable ladder. That is consistent with a large pool of newly replicated or otherwise differently packaged viral DNA being more accessible.

The total-DNA ladders show that host chromatin remains nucleosomal and that the assay can recover protected fragments in each cellular condition. The virus-specific Southern blot distinguishes viral DNA from this abundant host background, and the uninfected lane controls probe background. The conclusion concerns the dominant detectable viral population: productive cultures can contain both chromatinized templates in viral latency and accessible replication products. Absence of a ladder does not establish absence of every histone molecule, and differences in DNA recovery or nuclease accessibility should be considered before assigning a precise fraction of chromatinized genomes.

The cytoplasmic viral signal stays predominantly at high molecular size despite longer nuclease treatment. The viral DNA is protected from digestion, plausibly inside viral capsids or assembled particles. This differs from a nucleosomal ladder: a capsid can shield a whole genome instead of producing repeated small protected units. Release into the cytoplasm during productive infection makes particle-associated DNA a reasonable interpretation.

The virus-negative lane argues against nonspecific hybridization. Protection alone nevertheless does not prove that all detected particles are mature or infectious; an inaccessible compartment or another protective assembly could also shield DNA. Comparing intact material with material whose protective envelope or capsid has been disrupted would distinguish enclosure from intrinsic nuclease resistance of the DNA. Fractionation controls would address nuclear contamination. The result is about physical accessibility of viral DNA, not a quantitative infectivity assay.

The naked labelled DNA runs fastest. Reconstitution creates a slower nucleosome band, with a little residual unassembled DNA. Adding NVNA1 progressively generates several additional, more slowly migrating labelled species and reduces the unbound nucleosome population. These are consistent with ternary protein–DNA complexes containing DNA, histones and NVNA1, with increasing occupancy or altered assembly. The naked-DNA titration also shows several NVNA1–DNA species, reflecting different occupancy states on the repeat-containing fragment.

A mobility shift reports changes in charge, size and shape together. It cannot by itself establish that histones remain in every shifted species, or identify exact protein stoichiometries. In particular, similarity to a band in the naked-DNA lanes could indicate histone loss rather than merely another occupancy state. The specific-competitor experiment in the next part supplies the important compositional test: removal of NVNA1 can regenerate a nucleosome band, demonstrating retention of histones in the starting ternary population.

With nucleosomes alone, neither competitor substantially removes the main nucleosome band, although some free labelled DNA is present. With nucleosome–NVNA1 complexes, increasing specific competitor DNA removes the extra shifts and restores the nucleosome band. The starting shifted complexes therefore contained histones as well as NVNA1: competitor recognition sites draw NVNA1 away while leaving labelled DNA associated with histones.

nonspecific competitor DNA gives a different endpoint. The shifted population changes to a band matching the far-right NVNA1–naked-DNA control, rather than returning mainly to the nucleosome position. The labelled DNA remains bound to NVNA1 while histones can transfer to the excess competitor DNA. NVNA1 binding destabilizes the nucleosome against competitor-induced histone displacement. Remaining shifted DNA is not evidence that the histone octamer remained: its mobility must be compared with both controls. The nucleosome-only competition lanes show that competitor DNA alone is insufficient to cause the same conversion. Histone-specific detection would confirm the inferred component loss. A closely analogous ternary-complex and competition analysis was demonstrated for EBNA1; it provides a methodological precedent without establishing the identity of NV.^[ref]

About 80% of full-length-expressing biological cells have two conspicuous nuclear foci, whereas roughly 90% of biological cells expressing the deletion protein have none. Both proteins show nuclear fluorescence, so the result is not explained simply by complete exclusion of the deletion protein from the nucleus. The DNA-binding domain is needed for efficient focal accumulation at a small number of host sites. A plausible explanation is recognition of repeated host DNA sequences resembling the viral binding sites; clustered repeats and homotypic contacts would concentrate the protein enough to create visible foci.

Two spots are compatible with one locus on each homologous chromosome in a diploid biological cell. They do not prove diploidy, identify a chromosome, or exclude unresolved sister loci and cell-cycle effects. An alternative is DNA-dependent recruitment through a host complex. Matching protein abundance and confirming stability of the deletion construct would make the domain comparison stronger. Punctate fluorescence alone does not demonstrate a liquid condensate or show that a focus identifies an origin of replication.

Use fluorescent dCas9 to ask whether NVNA1 foci coincide with a defined host DNA locus. Targeting a candidate repeated region with CRISPR locus labelling would produce a locus marker in a second colour. Reproducible colocalization with full-length NVNA1, but not with a labelled unrelated locus, supports sequence-associated accumulation. A non-targeting guide and biological cells lacking NVNA1 control fluorescence and targeting background; matched expression and nuclear localization control the protein comparison. The inactive Cas9 is important because cleavage itself could create the chromosome damage being investigated.

A complementary causal test would alter the candidate host recognition region and ask whether focal accumulation is reduced while general nuclear NVNA1 remains. Independent edited clones, verification of the host alteration, and an appropriate restored host-site control would distinguish loss of recognition from clone-specific damage or copy-number changes. Colocalization localizes the protein but does not alone prove direct base-specific contact; the biochemical binding evidence supplies that separate argument. Fluorescent CRISPR marking of a repeated host locus has a direct precedent in the EBNA1 study.^[ref]

The normal patterns are A3, B2 and C4. In each, two principal DNA fluorescence in situ hybridization signals lie at corresponding positions on the two replicated sister chromatids. A single chromosome in mitosis has already replicated its DNA, so a unique locus normally has one copy on each sister, rather than two signals because two homologous chromosomes are being shown.

The other examples show a single unresolved or missing partner signal, extra fragmented signals, or an abnormal distribution. The images are small and relative intensities differ, especially in row C, so the appropriate criterion is the paired principal locus signals at matching positions, not perfect equality of brightness. Counts from many chromosomes, adequate optical resolution and hybridization controls are necessary before classifying borderline examples.

The locus frequently appears as an abnormal, fragile-site-like structure rather than a clean replicated pair. A1, B3 and C2 have one dominant signal instead of a clearly resolved sister pair; A2/A4, B1/B4 and C1/C3 show extra, split or irregularly distributed signal components. These patterns are compatible with incomplete replication, abnormal condensation of sister chromatids, or splitting and fragmentation of the repeat-containing region. A single signal can also result from unresolved sisters or inefficient hybridization, so it is not automatically a deletion.

The several small signals should not simply be counted as newly created intact copies: stretching, gaps and fragmentation can divide the fluorescent image of an existing locus. Conversely, amplification would require independent copy-number evidence. The fact that aberrant structures occur in non-infected biological cells indicates intrinsic vulnerability of this host region, rather than a requirement for NVNA1 in their initial appearance. These images alone do not distinguish an undercondensed but continuous DNA region from a genuine DNA double-strand break. Their sensitivity to replication inhibition provides the next mechanistic clue.

aphidicolin increases the abnormal-locus fraction from roughly 40% to about 55–60% in all three lines. Inhibition of replicative DNA polymerases increases replication stress at an intrinsically difficult-to-complete region. Tandem repeats can complicate fork progression or chromosome organization. Slower or incomplete synthesis leaves underreplicated DNA, unresolved replication intermediates or abnormal condensation as biological cells approach mitosis; these can appear as split signals or gaps and can predispose to actual breakage.

This is an increase of approximately 15–20 percentage points, not proof of a 15–20-fold change. The two independent measurements per condition support a reproducible direction, but the graph does not provide enough information for a precise significance calculation or a quantitative model of fork failure. aphidicolin need not bind NVNA1 or the repeat sequence directly. Because these are uninfected biological cells, the result establishes susceptibility of the host locus to replication stress independently of viral protein expression.

The large breakage frequencies occur mainly at supraphysiological NVNA1 levels; the probability at the mean latent level is not measured directly. At 20 ng/ml doxycycline, NVNA1 is already about twice the latent amount, and breakage is about 8%. At 50 ng/ml, the protein is approximately eightfold above latent levels and breakage about 25%; at 100 ng/ml, approximately sixteenfold and about 45–50%. Higher induction reaches roughly 60% while expression rises to about 21–24 times the latent level. The western blot loading control supports a protein-abundance comparison, although quantitative interpretation also requires unsaturated immunoblot detection.

Latent expression, defined as a ratio of one, lies below the lowest nonzero measured dose. Extrapolating a straight line from baseline and the twofold point would suggest a small frequency, but neither linearity nor a threshold is established. The justified conclusion is lower expected short-term breakage than in the strongly induced conditions, with a potentially important effect of modest upward fluctuations. Cell-to-cell variability, duration of expression and repeated divisions could make uncommon events consequential during a persistent infection. A percentage of broken chromosomes in this assay is not a patient's lifetime cancer probability. Doxycycline and tag controls are also needed to attribute the induced-cell phenotype specifically to NVNA1.

The evidence supports NVNA1 as a sequence-specific organizer of viral chromatin, with possible additional roles in nuclear retention and episome partitioning. Binding to the origin of replication and DNA bridging explain assembly at separated viral repeat arrays. Access to recognition sites in nucleosomes and weakening of histone–DNA association provide a plausible way to make an origin accessible to cellular replication machinery. The density-labelling result is consistent with a latent genome using a host-coordinated copying programme; it does not establish that NVNA1 is itself a DNA polymerase or DNA helicase.

Association with host chromosomal DNA could also retain episomes in the nucleus and help distribute them during biological cell division. Such tethering is a plausible maintenance function, but the experiments here do not directly visualize a physical bridge between an episome and a host chromosome. Binding at a vulnerable host repeat could instead be an incidental consequence of recognition specificity. The enrichment of host chromosome rearrangements supports a damage connection; it does not show that chromosome breakage is required for viral replication or that integration is part of the normal latent programme. chromatin opening and host-locus interference are mechanistic interpretations of the presented binding data, not proof of one obligatory replication pathway.

NVNA1 could contribute to cancer by increasing the chance of host chromosome damage and heritable rearrangements. Persistent occupancy of a chromosomal fragile site could obstruct replication or normal chromatin reassembly. Incompletely replicated or damaged DNA can break, mis-segregate and be repaired into deletions, gene fusions or copy-number alterations. Particular surviving rearrangements might remove a tumour suppressor gene or deregulate an oncogene, after which clonal selection could expand that lineage. A viral protein can therefore promote genomic instability without the viral genome having to integrate at every breakpoint.

The tumour-sequencing association is consistent with this mechanism but does not establish causality by itself. tumour type, pre-existing instability, infection detection sensitivity and cellular composition can confound an NV-positive/NV-negative comparison. The induction experiment strengthens the case that NVNA1 can damage the locus, while its high doses limit direct estimation of risk during ordinary viral latency. Very common infection is compatible with rare cancer because susceptible biological cell types, expression fluctuations, time and cooperating alterations all matter. A documented biological analogue links EBNA1 occupancy of a chromosome 11 repeat cluster to chromosome breakage and rearrangement.^[ref]

ToxB greatly reduces recognizable actin cables and actin patches. Untreated biological cells contain concentrated cortical structures, especially in buds, whereas treated biological cells show only weak diffuse staining even at ten times the exposure. The disappearance concerns actin filament organization and detectable F-actin, not necessarily destruction of the actin protein itself. actin monomer sequestration could leave substantial total actin present while eliminating most visible polymer.

Loss of actin cables should impair directed secretory-vesicle delivery and polarized cell growth; loss of actin patches should impair actin-dependent endocytosis. Disruption of the actomyosin machinery can also compromise cytokinesis. The rounded, poorly polarized appearance is consistent with these effects, but the images do not independently measure secretion, division rate or viability. A vehicle control and equal-exposure images are needed for quantitative fluorescence comparison; a longer exposure is useful for finding residual structures but prevents direct comparison of the displayed brightnesses.

The detectable cytoskeleton effect is substantially reversible after washout. Depolarized actin patches reappear first, reaching roughly 85% of biological cells near 20 minutes. Polarized actin patches subsequently increase to about 80%, while detectable actin cables recover later, reaching roughly 70–75% by the end of the time course. This argues against irreversible destruction of all cellular capacity to assemble actin.

Recovery is not instantaneous, and the population measurements do not prove that every previously treated biological cell recovers. Nor do they distinguish reuse of the existing actin pool from a contribution of new protein synthesis. A time-matched vehicle culture and a continuously treated culture would separate washout-dependent recovery from changes caused by handling or time alone. Reversibility of visible structures also does not by itself establish recovery of every physiological function.

Both structures turn over rapidly, with visible actin cables disappearing faster than actin patches under these conditions. Cable-positive biological cells fall from about 80% to essentially none within roughly two minutes. Polarized actin patches disappear over several minutes, while a transient depolarized-patch population persists before nearly all actin patches are lost by the end of the treatment time course.

Because ToxB binds actin monomers rather than existing actin filaments, a straightforward explanation is continuing normal disassembly without adequate replacement from assembly-competent actin monomers. The disappearance therefore reveals dynamic maintenance of structures that can look static in a fixed image. It does not show that the drug directly severs actin cables. Percentages of biological cells above a visibility threshold are not exponential decay curves for the lifetimes of individual actin filaments: cable thickness, staining sensitivity, actin monomer access and secondary loss of polarity can all affect the apparent timing. An analogous monomer-sequestering inhibitor established rapid yeast actin turnover in the classical study by Kathryn R. Ayscough and colleagues.^[ref]

actin patches can re-form, and can become polarized, before detectable actin cables return. Depolarized actin patches are abundant around 20 minutes after washout, when the cable curve remains essentially zero. By roughly 40 minutes many biological cells already have polarized actin patches, still with almost no visible actin cables. Thus a strict requirement for an already established visible cable network in patch assembly or initial patch polarization is inconsistent with these population data.

The converse is not demonstrated: actin cables recover only after actin patches have returned, so this experiment cannot establish that actin cables assemble independently of actin patches. It also cannot exclude sparse or very short actin filaments below the cable-detection threshold. The percentages do not follow the same individual biological cells, and temporal order alone does not prove a direct molecular dependence. The strongest conclusion is the one-way independence actually resolved by the graph, rather than complete mutual independence.

actin patches initially return in a depolarized distribution and then become concentrated at a growth pole. The depolarized fraction peaks near 20 minutes and subsequently falls as the polarized fraction rises. Patch assembly therefore recovers before normal spatial organization is restored.

A plausible cellular interpretation is recovery from disrupted trafficking and growth polarity, followed by establishment of a bud-associated growth site and renewed polarized secretion and endocytosis. Continued cell-cycle progression can also redistribute actin patches as biological cells grow and prepare to divide. The graph alone does not show that all biological cells pass synchronously through one particular cell-cycle stage, or that the recovered pole is the same pole used before treatment. Time-lapse imaging of the same biological cells and a bud or cell-cycle marker would distinguish restoration of an old site from selection of a new one.

ToxB strongly reduces sedimentable wild-type actin, whereas act1-117 shows little additional reduction from its already low baseline. Wild-type actin is mainly in the pellet without drug and mainly in the supernatant with drug. Using the approximate bar heights, the pelleted fraction changes from $740/(740+120)\approx 0.86$ to $280/(280+820)\approx 0.25$. Thus the drug suppresses polymer accumulation but does not eliminate the measured pellet entirely.

For act1-117, the pellet is only about one-third of the recovered signal even without drug, and remains near that fraction with drug: approximately $340/(340+570)\approx 0.37$ and $360/(360+660)\approx 0.35$. The mutant is therefore relatively resistant to the drug's further effect under this assay, but it is not a wild-type-quality polymerizer with an unchanged high polymer mass. These are approximate within-pair fractions; unequal total recoveries and loading limit precise quantitative comparison. sedimentation also requires confirmation that pellet material is filamentous rather than aggregated.

Sequestration of assembly-competent G-actin explains both inhibition of polymer formation and loss of pre-existing cellular structures. In a simple model, free actin monomer $G$ binds drug $D$ to form an assembly-incompetent complex $GD$. At a actin filament end the net addition rate is $v=k_{+}[G]-k_{-}$, so lowering free $[G]$ reduces elongation and can drive net shortening below the relevant actin critical concentration $C_c=k_{-}/k_{+}$. Formation of new nuclei is also strongly reduced when free actin monomer is depleted. Existing actin filaments can consequently disappear through ordinary turnover even though ToxB never binds them.

Binding could instead or additionally alter the actin monomer conformation or nucleotide state needed for productive assembly. The resistant mutant supports an interaction with actin, but resistance could reflect reduced drug affinity, an allosteric change or altered assembly properties. The available endpoints do not uniquely distinguish these possibilities. In particular, they provide no positive evidence for direct actin filament severing or actin filament capping by ToxB. A real example of actin-monomer sequestration and resistant-actin genetics is latrunculin A; this is an analogy, not a chemical identification of ToxB.^[ref]

A pyrene-actin assay can follow assembly continuously. A small labelled fraction mixed with otherwise unlabelled actin gives an increasing signal as the labelled subunits enter actin filaments, allowing comparison of lag, growth and plateau. Drug-only and labelled-monomer controls are essential because ToxB might alter fluorescence directly; comparable label incorporation and a polymer-mass calibration are needed to compare wild-type and mutant actin. An institutional description explains this polymerization-dependent fluorescence readout.^[ref]

Direct single-filament imaging by total internal reflection fluorescence microscopy can separately measure actin filament appearance, elongation and shortening, rather than inferring all three from bulk polymer mass. It requires matched surface and label conditions, since immobilization can perturb assembly. light scattering or turbidity can also follow assembly, but aggregates and changes in actin filament length or bundling complicate mass estimates. electron microscopy can verify actin filament morphology and length at selected times, although sampling and preparation make it less convenient for a continuous kinetic curve. Combining a bulk assay with direct actin filament imaging addresses different ambiguities.

The major problems are unequal recovered totals, absence of replication/error estimates, and ambiguity about what pellets. Wild-type supernatant plus pellet signal is roughly 860 units without drug and 1,100 with drug; the mutant totals also differ. Equal starting actin should give comparable total recovery after correcting for fraction volumes and loading. The graph does not specify such corrections, so comparing raw pellet heights alone is misleading. Fractions $P/(S+P)$ are more informative but still require comparable staining response and unbiased recovery.

The mutant's poor drug-free pelleting is biologically important and should not be hidden by calling it simply resistant. Independent preparations and replicate assays would establish whether that baseline is reproducible. One drug concentration and one nominal steady-state time cannot establish potency, binding affinity, assembly kinetics or attainment of a true steady state. The gel confirms an actin-sized band but does not preserve actin filament structure: denaturation occurs after separation. Short actin filaments can remain in the supernatant, and aggregates can pellet. Direct imaging, mass-balance controls, a monomer-only control and a linear densitometry calibration would make the interpretation substantially stronger.

Several concentrations reveal a sensitivity range and help distinguish resistance from a single-dose threshold effect. Increasing disc concentration increases the region in which diffusing drug exceeds the local growth-inhibitory concentration. The wild type has progressively larger clear zones, act1-117 has little or no detectable inhibition across the tested range, and act1-129 is inhibited much more strongly. The zero-drug disc provides a local control for the disc and vehicle; it is the fourth condition alongside the three nonzero concentrations.

A halo diameter is not directly proportional to a dissociation constant or a minimum inhibitory concentration: molecular diffusion, agar composition, uptake and growth rate contribute. Overlapping large halos can also limit comparison at high doses. Matched lawns, solvent exposure and incubation are necessary, and a quantitative growth assay in uniform drug concentrations would give a cleaner concentration–response curve. Multiple disc doses prevent a lack of inhibition at one weak dose from being mistaken for absolute resistance.

Disrupting the dynamic actin network compromises processes required for sustained proliferation: endocytosis, directed delivery of cell membrane and cell-wall material, maintenance of polarized cell growth and successful cytokinesis. Failure of these actin-dependent functions can cause growth arrest and, under sufficiently damaging conditions, loss of viability. The altered sensitivity of actin mutants supports an actin-related mechanism, with their different assembly properties potentially changing the reserve of functional cytoskeleton.

A clear zone itself establishes failure to form a visible lawn, not necessarily death. biological cells might remain viable but fail to bud or divide while drug is present. Recovery after drug removal and subsequent colony formation would distinguish reversible arrest from killing. The experiment also does not identify which actin-dependent process first becomes limiting; matched measurements of trafficking, budding and division would be needed for that ordering.

Test whether cellular drug effects persist when actin is protected by a drug-resistant allele. Compare otherwise matched wild-type and act1-117 biological cells across a drug-concentration range, measuring growth or colony formation together with actin organization and a relevant cellular phenotype. Each strain needs a vehicle-only baseline because the mutant already has abnormal intrinsic assembly. If the resistant strain maintains its actin network and the normal actin-dependent functions but still develops another reproducible defect, that residual effect is a candidate off-target drug effect. Comparable intracellular exposure is important: resistance caused by lower uptake would not protect only the intended target.

Conversely, coordinated rescue of the actin and growth phenotypes supports an on-target explanation over that dose range, without proving the absence of every other molecular interaction. Reintroducing wild-type actin or using another independently resistant allele helps separate the actin substitution from unrelated genetic background effects. A candidate secondary target would need its own binding or functional assay and a selective rescue test. A second actin inhibitor giving the same phenotype is supportive but cannot alone exclude shared secondary effects.

Experiment 2: relative to untreated wild-type actin, actin monomer sequestration predicts a longer apparent actin nucleation lag, a smaller elongation slope, and a lower steady-state polymer mass. At sufficiently strong binding the trace could remain nearly flat rather than displaying clearly separated phases. The wild-type sedimentation data support a lower endpoint, but do not establish the exact kinetic changes or whether the time to plateau is longer or shorter.

Experiment 3: the halo result does not determine the drug-free actin polymerization curve of act1-129. A mutation that mainly raises drug affinity could have a nearly wild-type curve without drug. A mutation that intrinsically destabilizes actin filaments or impairs actin nucleation could instead prolong the lag, reduce growth and lower the plateau. Thus a wild-type-like untreated curve is a useful conditional reference prediction, not a result that follows from cellular hypersensitivity.

Experiment 4: act1-129 is about sixfold more sensitive in the cellular assay. If that reflects a stronger direct effect of ToxB on its actin monomers, predict greater suppression than in experiment 2: a longer or effectively absent actin nucleation phase, slower or undetectable elongation, and a still lower plateau relative to its own drug-free control. It could be almost flat. However, cellular hypersensitivity could also arise from reduced functional reserve or altered interactions with other proteins; it does not guarantee stronger inhibition of purified actin. These alternatives are exactly what the comparison with experiment 3 resolves. No numerical lag, slope or plateau can be calculated from halo sizes alone.

The three resistant substitutions map near one another in the folded actin monomer, near the protein binding site for the nucleotide. This cluster identifies a candidate region involved in drug recognition or in the conformational response to binding. Neighbouring residues in three-dimensional structure can help form a pocket even when they are not adjacent in the protein primary structure. Reduced drug binding at this region would connect the structural map to the resistant phenotype.

The map does not show a bound ToxB molecule. Substitutions could act indirectly by changing folding, nucleotide exchange or the assembly-competent conformation. Proximity to ATP does not prove competition for the ATP-binding site, and the mutant's abnormal baseline actin polymerization makes an allosteric explanation particularly relevant. Direct binding measurements on comparably folded wild-type and mutant actin monomers, together with nucleotide-binding controls and a ligand-bound structure, would distinguish these models. The allele/residue labels are interpreted as defined in this paper; no identification of their original experimental sequence substitutions is required.

Efficient and timely budding requires the normal actin network, but some initial polarized cell growth remains possible when visible actin filaments are greatly depleted. Around 40% of control biological cells have new buds by two hours, rising to nearly 60% by six hours. Drug-treated biological cells show almost no budding at two hours but roughly 15–20% at four to six hours, and the phase images confirm small buds despite loss of normal bright actin structures.

The result therefore supports a large delay and reduction, rather than an absolute block to every initiation event. Polarity cues or localized membrane-fusion machinery could remain spatially organized without normal long actin cables. The images and bud counts do not establish completion of a daughter-cell cycle, normal cytokinesis or indefinite proliferation. Residual actin filaments below detection remain an alternative contributor. This distinction between initial bud emergence and completion of growth was directly examined in a quiescence-exit study.^[ref]

The new bud contains newly deposited wall rather than simply inheriting a stretched patch of the mother's old labelled wall. concanavalin A conjugated to FITC was applied before growth resumed, so it marks the pre-existing accessible biological cell surface. The bright mother outline persists while the emerging bud is weakly labelled or unlabelled. That spatial contrast places substantial new, unlabelled wall material at the growth site. Drug-treated biological cells that eventually bud show that at least some localized new wall deposition still occurs under treatment.

The pulse label does not mark all wall made subsequently, and it does not prove that absolutely no new material is inserted elsewhere in the mother. Signal dilution, shedding and accessibility can affect brightness. A second distinguishable wall label applied after refeeding would more directly map new deposition. If the original lectin remained free in the medium, it would also bind newly exposed wall, so the interpretation assumes the stated prelabelling step functions as a pulse rather than continuous staining.

Some cell membrane delivery and fusion must continue in the biological cells whose buds actually grow, but it need not use normal long-range cable transport. secretory vesicles can move by molecular diffusion or other non-directed motion and be preferentially captured, tethered and fused where a surviving polarity cue concentrates the relevant vesicle docking machinery. Spatial selectivity can therefore reside in the destination rather than in directed travel over the entire route. Less efficient delivery is consistent with delayed budding and small buds.

Short residual actin tracks could also contribute; the experiment does not prove that every actin filament is absent. Neither bud shape nor Con-A staining directly measures vesicle trajectories or fusion events. Tracking secretory vesicles together with a membrane-fusion reporter and a polarity marker would distinguish directed runs from molecular diffusion followed by localized capture, with expression and imaging controls for reporter effects. Random arrival with selective vesicle docking is a published mechanistic proposal for this physiological context, rather than a demonstrated trajectory in the present images.^[ref]

The weak phalloidin signal could include sparse or very short residual actin filaments, together with nonspecific background; it is not a direct image of G-actin. phalloidin preferentially binds filamentous actin, so genuinely specific residual signal would indicate some polymeric actin. Long exposure also amplifies autofluorescence, out-of-focus light and nonspecific staining. Vehicle controls, unstained biological cells, matched acquisition settings and background subtraction are needed before assigning a small residual signal to actin filaments.

For wavelength $\lambda$ and numerical aperture $\mathrm{NA}$, the Rayleigh criterion gives a conventional lateral resolution of roughly $d\approx 0.61\lambda /\mathrm{NA}$, typically a few hundred nanometres under these conditions, far larger than the roughly 7-nm actin filament diameter. It cannot resolve every short actin filament, distinguish all closely spaced actin filaments, or infer polymer mass directly from the displayed intensity. The tenfold exposure change is not itself a calibrated tenfold decrease in F-actin. Fixation, dye accessibility and detector saturation introduce further uncertainty.

Super-resolution fluorescence microscopy could localize remaining labelled structures more precisely, while electron microscopy or cryo-electron tomography could test ultrastructure, subject to preservation and sampling limits. Biochemical separation of polymeric and soluble actin, with the mass-balance and aggregation controls already discussed, supplies an independent population measurement. A live actin reporter can test dynamics but must be checked for perturbation of assembly. Agreement between these approaches would be stronger than concluding complete actin filament absence from weak conventional staining alone.